Citigroup Initiates Coverage On Catalyst Pharmaceuticals with Buy Rating, Announces Price Target of $27
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow initiates coverage on Catalyst Pharmaceuticals with a Buy rating and a price target of $27.

March 14, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has initiated coverage on Catalyst Pharmaceuticals with a Buy rating and set a price target of $27.
The initiation of coverage by Citigroup with a Buy rating and a price target significantly higher than the current trading price is likely to be viewed positively by investors. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100